CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
Margaret L. Green,Margaret L. Green,Wendy M. Leisenring,Wendy M. Leisenring,Hu Xie,Roland B. Walter,Roland B. Walter,Marco Mielcarek,Marco Mielcarek,Brenda M. Sandmaier,Brenda M. Sandmaier,Stanley R. Riddell,Stanley R. Riddell,Michael Boeckh,Michael Boeckh +14 more
TLDR
A modest reduction in early relapse risk after HCT associated with CMV reactivation is demonstrated in a large cohort of patients without a benefit in overall survival.About:
This article is published in Blood.The article was published on 2013-08-15 and is currently open access. It has received 251 citations till now. The article focuses on the topics: Myeloid leukemia & Myelodysplastic syndromes.read more
Citations
More filters
Journal ArticleDOI
Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.
Heinrich Schlums,Frank Cichocki,Frank Cichocki,Bianca Tesi,Jakob Theorell,Vivien Béziat,Tim D. Holmes,Hongya Han,Samuel C. C. Chiang,Bree Foley,Kristin Mattsson,Stella Larsson,Marie Schaffer,Karl-Johan Malmberg,Karl-Johan Malmberg,Karl-Johan Malmberg,Hans-Gustaf Ljunggren,Jeffrey S. Miller,Yenan T. Bryceson,Yenan T. Bryceson +19 more
TL;DR: The emergence of diverse subsets of human NK cells selectively lacking expression of signaling proteins after human cytomegalovirus (HCMV) infection is described, uncovering a spectrum of epigenetically unique adaptive NK cell subsets that diversify in response to viral infection and have distinct functional capabilities compared to canonical NK cells.
Journal ArticleDOI
Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis
Pierre Teira,Minoo Battiwalla,Muthalagu Ramanathan,A. John Barrett,Kwang Woo Ahn,Min Chen,Jaime S. Green,Ayman Saad,Joseph H. Antin,Bipin N. Savani,Hillard M. Lazarus,Matthew D. Seftel,Wael Saber,David I. Marks,Mahmoud Aljurf,Maxim Norkin,John R. Wingard,Caroline A. Lindemans,Michael Boeckh,Marcie L. Riches,Jeffery J. Auletta +20 more
TL;DR: CMV reactivation continues to remain a risk factor for poor posttransplant outcomes and does not seem to confer protection against hematologic disease relapse.
Journal ArticleDOI
Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
Margaret L. Green,Margaret L. Green,Wendy M. Leisenring,Wendy M. Leisenring,Hu Xie,T. Christopher Mast,Yadong Cui,Brenda M. Sandmaier,Brenda M. Sandmaier,Mohamed L. Sorror,Mohamed L. Sorror,Sonia Goyal,Sezen Özkök,Jessica Yi,Farah Sahoo,Louise E. Kimball,Keith R. Jerome,Keith R. Jerome,Morgan A. Marks,Michael Boeckh,Michael Boeckh +20 more
TL;DR: Cytomegalovirus viraemia is associated with an increased risk of overall mortality in the first year after haemopoietic stem cell transplantation, independent of the use of pre-emptive therapy, and with evidence of a positive dose-response relationship.
Journal ArticleDOI
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Per Ljungman,Rafael de la Cámara,Christine Robin,Roberto Crocchiolo,Hermann Einsele,Joshua A. Hill,Petr Hubacek,David Navarro,Catherine Cordonnier,Katherine N. Ward +9 more
TL;DR: This Review summarises the reviewed literature and the recommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignancies and covers diagnosis, preventive strategies such as prophylaxis and pre-emptive therapy, and management.
Journal ArticleDOI
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
TL;DR: A growing number of scientific discoveries into pathways that both activate and suppress NK cell function, as well as methods to sensitize tumours to NK cell cytotoxicity, have led to the development of numerous pharmacological and genetic methods to enhance NK cell antitumour immunity.
References
More filters
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal Article
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka,Daniel J. Weisdorf,Paul J. Martin,Hans G. Klingemann,Beatty P,Hows J,Thomas Ed +6 more
TL;DR: Reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GV HD corrected for graft failure and potential interventions for early relapse.
Journal ArticleDOI
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
Loredana Ruggeri,Marusca Capanni,Elena Urbani,Katia Perruccio,Warren D. Shlomchik,Antonella Tosti,Sabrina Posati,Daniela Rogaia,Francesco Frassoni,Franco Aversa,Massimo F. Martelli,Andrea Velardi +11 more
TL;DR: It is shown that donor-versus-recipient natural killer (NK)–cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD in human transplants and in mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GV HD.
Journal ArticleDOI
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade,Robert Kerrin Hills,Anthony V. Moorman,Helen Walker,S Chatters,Anthony H. Goldstone,Keith Wheatley,Christine J. Harrison,Alan Kenneth Burnett +8 more
TL;DR: Analysis of outcomes of 5876 patients treated in Medical Research Council trials allows more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML.
Journal ArticleDOI
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study
TL;DR: Delaying the start of ganciclovir until highgrade antigenemia and discontinuing gancIClovir based on negative antigenemia results in more CMV disease by day 100 than gancinglovir administered at engraftment, however, gancclovir at engRAFTment is associated with more early invasive fungal infections and more late CMV Disease resulting in similar survival rates.
Related Papers (5)
Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis
Pierre Teira,Minoo Battiwalla,Muthalagu Ramanathan,A. John Barrett,Kwang Woo Ahn,Min Chen,Jaime S. Green,Ayman Saad,Joseph H. Antin,Bipin N. Savani,Hillard M. Lazarus,Matthew D. Seftel,Wael Saber,David I. Marks,Mahmoud Aljurf,Maxim Norkin,John R. Wingard,Caroline A. Lindemans,Michael Boeckh,Marcie L. Riches,Jeffery J. Auletta +20 more